Evaluation of cancer stemness properties in residual tumor tissue after treatment with BTZ alone revealed increased CD133 expression to 188.7 ± 26.7% (P < 0.001) and ALDH3A1 expression to 146.5 ± 24.7% of controls (P < 0.005; Fig. 6C). This evidence concerns the gene ALDH3A1 and neoplasm.